Basel, 21 July 2009 – Lonza has decided to combine the Exclusive Synthesis and Biopharmaceutical business sectors into one single division called Lonza Custom Manufacturing in order to enhance synergies in Sales & Marketing and on the operational side. This newly merged division will be jointly led by Stephan Kutzer and Uwe H. Boehlke respectively Heads of the Biopharmaceuticals and Exclusive Synthesis business sectors and both will continue to report to the CEO, Stefan Borgas. These changes are effective from today.
About Lonza
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.
